Icon Group is Australia’s largest dedicated provider of cancer care with a growing reach into Asia and New Zealand. The group is built on a strong but simple vision – to deliver the best care possible, to as many people as possible, as close to home as possible.
The Group is backed by a consortium of global private investment firms including Goldman Sachs Principal Investment Area (GS PIA), Pagoda Investments and Queensland Investment Corporation (QIC). Headquartered in Hong Kong, Goldman Sachs boasts a strong portfolio of leading international healthcare investments. Pagoda Investments is a global private equity fund focussing on innovative technology, healthcare and advanced manufacturing, and QIC is an Australian investment firm owned by the Queensland Government with strong local and international business networks with a long-term investment mind-set.
The Group came together in 2015, however the businesses that form the Group have been pillars of the Australian and Asian healthcare communities for decades. These leaders – our founders, shared a belief that patients in Australia and abroad would benefit from a more innovative and dynamic approach to cancer care. Through this vision, Icon has created a unique integrated, end-to-end service model that leverages the strengths of a diverse, experienced multi-disciplinary team. The group delivers all aspects of quality cancer care, including chemotherapy, radiation therapy, and treatment for blood disorders, colorectal surgery, pharmacy and chemotherapy compounding.
In the past three years the group has grown significantly now with 30 cancer centres in Australia (including radiation oncology centres, medical oncology centres, as well as integrated centres offering all aspects of cancer care), seven sites in Singapore, one in Mainland China and four clinics in Hong Kong as well as a joint venture in New Zealand and a service agreement in Vietnam. Icon continues to open more centres, with several radiation oncology centres underway in Mainland China and Australia continuing to provide more care to where it is needed.
With a strong focus on innovation and investment in technology based solutions, as well as partnerships with peak international bodies such as the Union for International Cancer Control, Icon is proudly at the forefront of addressing the global cancer burden.
For more information on Icon Group visit https://icongroup.global